SECONDARY MYELOFIBROSIS

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This study tests whether adding iadademstat to the standard drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. About 62 adults whose disease has progressed to a more aggressive phase will be ra…

This study tests whether adding the drug ruxolitinib to standard transplant care can prevent a serious side effect called graft-versus-host disease (GVHD) in older adults with myelofibrosis or related blood cancers. About 50 participants will receive ruxolitinib before, during, a…

This study is for people with myelofibrosis, a type of bone marrow cancer. It tests giving a JAK inhibitor drug before, during, and after a stem cell transplant from a half-matched donor. The goal is to reduce a serious side effect called graft-versus-host disease without raising…

This study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…

This study is a registry that will follow 200 people in Germany with myelofibrosis and anemia. It will collect information on which treatments are used, how well they work, and how patients feel. The goal is to better understand current care and outcomes, not to test a new drug.